Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
471
Views
26
CrossRef citations to date
0
Altmetric
Letter to the Editor

Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma

Prakash Ambadya Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Laszlo Szidonyaa Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Jenny Firkinsa Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Jessica Jamesa Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Kirsten Johanssona Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Tricia Whitea Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Caroline Jezierskia Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Nancy D. Doolittlea Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
&
Edward A. Neuwelta Department of Neurology, Oregon Health & Science University, Portland, OR, USA; ;b Department of Neurosurgery, Portland Veterans Affairs Medical Center, Portland, OR, USACorrespondence[email protected]
View further author information
 show all
Pages 515-518 | Received 20 Feb 2018, Accepted 13 May 2018, Published online: 22 Jul 2018

References

  • Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–e227.
  • Jacoline B, Samar I, Katerina B, et al. Effect of rituximab in primary central nervous system lymphoma – results of the randomized phase III HOVON 105/ALLG NHL 24 study [Abstract]. Blood. 2018;130:582.
  • Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80:159–165.
  • Ambady P, Holdhoff M, Bonekamp D, et al. Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS. Oncol. 2015;4:393–398.
  • Ambady P, Fu R, Netto JP, et al. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barriers CNS. 2017;14:16.
  • Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19:742–749.
  • Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26:2512–2518.
  • Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18:76–83.
  • Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol. 2012;14:101–108.
  • Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–4244.
  • Hattab EM, Martin SE, Al-Khatib SM, et al. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol. 2010;23:235–243.
  • Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3073.
  • Kohrt HE, Houot R, Marabelle A, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4:511–527.
  • Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study. J Clin Oncol. 2017;35:120.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.